These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17405740)

  • 1. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
    Steiner M; Matthes-Martin S; Attarbaschi A; Lawitschka A; Minkov M; Mittheisz E; Fritsch G; Lion T; Zoubek A; Gadner H
    Haematologica; 2007 Jan; 92(1):e3-4. PubMed ID: 17405740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
    Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
    Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
    Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
    Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P; Sarosiek T; Szczylik C
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
    Dorsey MJ; Petrovic A; Morrow MR; Dishaw LJ; Sleasman JW
    Immunol Res; 2009; 44(1-3):179-84. PubMed ID: 19471859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis.
    Cooper N; Rao K; Goulden N; Webb D; Amrolia P; Veys P
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S47-50. PubMed ID: 18978744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Refractory Langerhans Cell Histiocytosis Complicated with Hemophagocytic Lymphohistiocytosis Rescued by Cord Blood Transplantation with Reduced-intensity Conditioning.
    Washio K; Muraoka M; Kanamitsu K; Oda M; Shimada A
    Acta Med Okayama; 2017 Jun; 71(3):249-254. PubMed ID: 28655945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
    Chakrabarti S; Handa SK; Bryon RJ; Griffiths MJ; Milligan DW
    Transplantation; 2001 Jul; 72(2):340-2. PubMed ID: 11477365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
    Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
    Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
    Blaise D; Vey N; Faucher C; Mohty M
    Haematologica; 2007 Apr; 92(4):533-41. PubMed ID: 17488664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
    Nagi W; Lim ZY; Krishnamurthy P; Potter V; Tindell V; Reiff-Zall L; Abdullah A; Lea N; Kenyon M; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2011 Aug; 35(8):998-1000. PubMed ID: 21704371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
    Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
    Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.